Barney S. Graham

Barney S. Graham

Top Cited Scholar 2026
Auto-generated profile, based on publicly available information

Barney S. Graham

Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 March 2020 in Science
Verified
Journal Article
Open access
PDF file
DWDaniel Wrapp
Daniel Wrapp
NWNianshuang Wang
Nianshuang Wang
KCKizzmekia S. Corbett
Kizzmekia S. Corbett
JGJory A. Goldsmith
Jory A. Goldsmith
CHChing-Lin Hsieh
Ching-Lin Hsieh
JMJason McLellan
Jason McLellan
The outbreak of a novel coronavirus (2019-nCoV) represents a pandemic threat that has been declared a public health emergency of international concern. The CoV spike (S) glycoprotein is a key target for vaccines, therapeutic antibodies, and diagnostics. To facilitate medical countermeasure development, we determined a 3.5-angstrom-resolution cryo–electron microscopy structure of the 2019-nCoV S trimer in the prefusion conformation. The predominant state of the trimer has one of the three receptor-binding domains (RBDs) rotated up in a receptor-accessible conformation. We also provide biophysical and structural evidence that the 2019-nCoV S protein binds angiotensin-converting enzyme 2 (ACE2) with higher affinity than does severe acute respiratory syndrome (SARS)-CoV S. Additionally, we tested several published SARS-CoV RBD-specific monoclonal antibodies and found that they do not have appreciable binding to 2019-nCoV S, suggesting that antibody cross-reactivity may be limited between the two RBDs. The structure of 2019-nCoV S should enable the rapid development and evaluation of medical countermeasures to address the ongoing public health crisis.

5 August 2020 in Nature
Verified
Journal Article
Closed access
PDF file
KCKizzmekia S. Corbett
Kizzmekia S. Corbett
DEDarin K. Edwards
Darin K. Edwards
SLSarah R. Leist
Sarah R. Leist
OAOlubukola M. Abiona
Olubukola M. Abiona
SBSeyhan Boyoglu-Barnum
Seyhan Boyoglu-Barnum
BGBarney S. Graham
Barney S. Graham

17 December 2020 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
EAEvan Anderson
Evan Anderson
NRNadine G. Rouphael
Nadine G. Rouphael
AWAlicia T. Widge
Alicia T. Widge
LJLisa A. Jackson
Lisa A. Jackson
PRPaul C. Roberts
Paul C. Roberts
JBJohn H. Beigel
John H. Beigel
Testing of vaccine candidates to prevent infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in an older population is important, since increased incidences of illness and death from coronavirus disease 2019 (Covid-19) have been associated with an older age. We conducted a phase 1, dose-escalation, open-label trial of a messenger RNA vaccine, mRNA-1273, which encodes the stabilized prefusion SARS-CoV-2 spike protein (S-2P) in healthy adults. The trial was expanded to include 40 older adults, who were stratified according to age (56 to 70 years or ≥71 years). All the participants were assigned sequentially to receive two doses of either 25 μg or 100 μg of vaccine administered 28 days apart. Solicited adverse events were predominantly mild or moderate in severity and most frequently included fatigue, chills, headache, myalgia, and pain at the injection site. Such adverse events were dose-dependent and were more common after the second immunization. Binding-antibody responses increased rapidly after the first immunization. By day 57, among the participants who received the 25-μg dose, the anti–S-2P geometric mean titer (GMT) was 323,945 among those between the ages of 56 and 70 years and 1,128,391 among those who were 71 years of age or older; among the participants who received the 100-μg dose, the GMT in the two age subgroups was 1,183,066 and 3,638,522, respectively. After the second immunization, serum neutralizing activity was detected in all the participants by multiple methods. Binding- and neutralizing-antibody responses appeared to be similar to those previously reported among vaccine recipients between the ages of 18 and 55 years and were above the median of a panel of controls who had donated convalescent serum. The vaccine elicited a strong CD4 cytokine response involving type 1 helper T cells. In this small study involving older adults, adverse events associated with the mRNA-1273 vaccine were mainly mild or moderate. The 100-μg dose induced higher binding- and neutralizing-antibody titers than the 25-μg dose, which supports the use of the 100-μg dose in a phase 3 vaccine trial. (Funded by the National Institute of Allergy and Infectious Diseases and others; mRNA-1273 Study ClinicalTrials.gov number, NCT04283461.)

1 November 2013 in Science
Verified
Journal Article
Closed access
PDF file
JMJason McLellan
Jason McLellan
MCMan Chen
Man Chen
MJM. Gordon Joyce
M. Gordon Joyce
MSMallika Sastry
Mallika Sastry
GSGuillaume B. E. Stewart-Jones
Guillaume B. E. Stewart-Jones
PKPeter D. Kwong
Peter D. Kwong
Designer Vaccine: Respiratory syncytial virus (RSV) is one of the last remaining childhood diseases without an approved vaccine. Using a structure-based approach, McLellan et al. (p. 592 ) designed over 150 fusion glycoprotein variants, assessed their antibody reactivity, determined crystal structures of stabilized variants, and measured their ability to elicit protective responses. This approach yielded an immunogen that elicits higher protective responses than the postfusion form of the fusion glycoprotein, which is one of the current leading RSV vaccine candidates entering clinical trials. Importantly, highly protective responses were elicited in both mice and macaques.

15 October 2020 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
KCKizzmekia S. Corbett
Kizzmekia S. Corbett
BFBarbara Flynn
Barbara Flynn
KFKathryn E. Foulds
Kathryn E. Foulds
JFJoseph R. Francica
Joseph R. Francica
SBSeyhan Boyoglu-Barnum
Seyhan Boyoglu-Barnum
BGBarney S. Graham
Barney S. Graham
Vaccines to prevent coronavirus disease 2019 (Covid-19) are urgently needed. The effect of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines on viral replication in both upper and lower airways is important to evaluate in nonhuman primates. Nonhuman primates received 10 or 100 μg of mRNA-1273, a vaccine encoding the prefusion-stabilized spike protein of SARS-CoV-2, or no vaccine. Antibody and T-cell responses were assessed before upper- and lower-airway challenge with SARS-CoV-2. Active viral replication and viral genomes in bronchoalveolar-lavage (BAL) fluid and nasal swab specimens were assessed by polymerase chain reaction, and histopathological analysis and viral quantification were performed on lung-tissue specimens. The mRNA-1273 vaccine candidate induced antibody levels exceeding those in human convalescent-phase serum, with live-virus reciprocal 50% inhibitory dilution (ID50) geometric mean titers of 501 in the 10-μg dose group and 3481 in the 100-μg dose group. Vaccination induced type 1 helper T-cell (Th1)–biased CD4 T-cell responses and low or undetectable Th2 or CD8 T-cell responses. Viral replication was not detectable in BAL fluid by day 2 after challenge in seven of eight animals in both vaccinated groups. No viral replication was detectable in the nose of any of the eight animals in the 100-μg dose group by day 2 after challenge, and limited inflammation or detectable viral genome or antigen was noted in lungs of animals in either vaccine group. Vaccination of nonhuman primates with mRNA-1273 induced robust SARS-CoV-2 neutralizing activity, rapid protection in the upper and lower airways, and no pathologic changes in the lung. (Funded by the National Institutes of Health and others.)

29 May 2020 in Science
Verified
Journal Article
Open access
PDF file
BGBarney S. Graham
Barney S. Graham
Finding the fastest pathway to vaccine availability includes the avoidance of safety pitfalls